SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Opinion
How the FDA Is Accelerating Cell and Gene Therapy’s Next Chapter
Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, actively working to remove obstacles to innovation.
November 14, 2025
 · 
6 min read
 · 
Anshul Mangal
Shanghai.China-Feb.25th 2022: Pfizer company sign on office building. Pharmaceutical and biotechnology corporation
Mergers & acquisitions
Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama
Speaking at a conference this morning, Pfizer CEO Albert Bourla suggested that Metsera’s therapies could begin hitting the market in 2028.
November 13, 2025
 · 
1 min read
 · 
Annalee Armstrong
Paper red boat sailing in the ocean or sea, travel concept. Blue sea waves layers. Modern paper art style 3d render
Editorial
FDA’s Bad Rap: Pazdur Steps Up as Agency Continues To Take on Water
Unpredictable communication and a lack of transparency are eroding the industry’s and the public’s trust. The FDA, experts agree, needs to take control of the narrative.
November 13, 2025
 · 
8 min read
 · 
Jef Akst
arrow down stock market investment global red technology background. Global economic slowdown and crisis. vector illustration fantastic technology.
RNA editing
Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal
Korro Bio is moving back to square one as a preclinical biotech after the failure of KRRO-110 in alpha-1 antitrypsin deficiency. The company’s stock is down 80% on all the news.
November 13, 2025
 · 
3 min read
 · 
Annalee Armstrong
The factor that changes everything. A critical break. A sudden change in plans. A threat and a danger. Recover from the blow and get back on course. Severe stress. Withstand the blow.
Obesity
Zealand Freezes Mid-Stage Obesity Asset To Focus on More Differentiated Drugs
The decision to pause dapiglutide will help Zealand focus investment into assets that have “the greatest potential for clinical differentiation” in obesity.
November 13, 2025
 · 
2 min read
 · 
Tristan Manalac
AbbVie's office in South San Francisco, California
Layoffs
AbbVie Ends 11-Year Relationship With Calico, Lays Off 100+
In January, AbbVie and Calico’s fosigotifator failed to show significant signs of efficacy in the HEALEY ALS platform trial for amyotrophic lateral sclerosis.
November 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Collage image sketch of tired girl sleeping home nightmare monster in room isolated on drawing background.
Neuroscience
Alkermes Pushes Narcolepsy Program to Phase III With ‘Highly Competitive’ Mid-Stage Data
Alixorexton’s Phase II performance sets it up for late-stage success, according to analysts at Truist Securities. Alkermes expects to launch a global late-stage program early next year for narcolepsy type 2.
November 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).
Rare diseases
FDA Unwraps ‘Plausible Mechanism Pathway’ for Personalized Therapies
The plausible mechanism pathway “could accelerate gene therapy/editing development,” analysts at William Blair said Thursday, while adding that additional clarity is needed.
November 13, 2025
 · 
3 min read
 · 
Tristan Manalac
Upward arrow on the background of the flag of China. Paper plane. Economic recovery. Copy space. Business. Background.
China
Recently Launched Third Arc Turns to China for Cancer T Cell Engagers
The back-heavy deal includes a $5 million upfront payment for two novel T cell engagers, though the companies have yet to disclose priority indications.
November 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS